Drugs / Matrix-M2
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01667341 | Jul 2012 → May 2014 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02515175 | Nov 2015 → Jul 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02300142 | Jan 2015 → Jun 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02114060 | Jul 2014 → Feb 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03146403 Background | May → Dec 2017 | genital herpes, herpes simplex type 2 infectious disease | Genocea Biosciences, Inc. | Terminated | Missed primary Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matrix-M2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03146403 ↗ |
| Modality | Other / unclassified | “Matrix-M2 Adjuvant” NCT02300142 ↗ |
| Route | Intramuscular | “IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.” NCT01667341 ↗ |